Nordic Nanovector is expanding its foothold in cancer-fighting ADCs. The Oslo-based biotech has inked a leukaemia pact with Wilex subsidiary Heidelberg Pharma.
https://european-biotechnology.com/wp-content/uploads/2024/04/20161026-leukaemias.jpg450800Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-10-26 09:47:362016-10-26 09:47:36Nordic Nanovector in blood cancer pact
Miquel A. Pericàs has taken over as general director of the Barcelona Institute of Science and Technology (BIST). The chemical engineer has been holding the position of director of the Institute of Chemical Research of Catalonia since 2000.
https://european-biotechnology.com/wp-content/uploads/2024/04/miquel-pericas.jpg473420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-10-25 09:50:492016-10-25 09:50:49BIST: Distinguished director
Trial transparency has been a hotly debated topic over the last months, but now, the EMA is turning words into action. The agency will allow public access to clinical trial reports, starting now.
3P Biopharmaceuticals has hired Andrew Carver as its new Senior Head of Business Development. Carver joins 3P from UK-based CDMO Fujifilm Diosynth Biotechnology.
After being leaderless for over a year, EffRx has a new CEO. In October, EffRx announced that Lorenzo Bosisio has taken over the company’s helm in July.
New name, new outlook: blood disorder specialist Dilaforette will be known as Modus Therapeutics Holding from here on out. The Swedish company also announced an intention to float in the near future.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2016-10-20 11:21:042016-10-20 11:21:04Dilaforette: Going public with a new name
Spanish start-ups, take heed: One of the biggest biotech funds in Southern Europe has just been closed by Ysios Capital. The Spanish venture firm raised €126.4m to be reinvested in European biotech, medtech and diagnostics companies.
Swiss oncology expert Nouscom has appointed Marina Udier Blagovic as its Chief Operating Officer. The position has been newly created to drive all aspects of business operations and business development.
https://european-biotechnology.com/wp-content/uploads/2024/04/marina-udier-blagovic.jpg430382h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-10-19 07:09:002016-10-19 07:09:00Nouscom: New hire for operations
Cambridge-based drug discovery company Crescendo Biologics Ltd has named Theodora Harold its Chief Financial Officer. She has held this position in several early stage and growing biotechs.
Nordic Nanovector in blood cancer pact
Latest NewsThermo Scientific DreamTaq DNA Polymerase
ProductsThe enhanced Taq DNA polymerase, available in standard and hot-start formats, offers a balance between performance and value.
BIST: Distinguished director
AppointmentsEMA unveils trial data
Latest News3P Biopharmaceuticals: Business Developer
AppointmentsEffRx Pharmaceuticals: Filling a vacancy
AppointmentsDilaforette: Going public with a new name
Latest NewsNew name, new outlook: blood disorder specialist Dilaforette will be known as Modus Therapeutics Holding from here on out. The Swedish company also announced an intention to float in the near future.
Ysios closes €126m BioFund
Latest NewsSpanish start-ups, take heed: One of the biggest biotech funds in Southern Europe has just been closed by Ysios Capital. The Spanish venture firm raised €126.4m to be reinvested in European biotech, medtech and diagnostics companies.
Nouscom: New hire for operations
AppointmentsCrescendo Biologics: Finance pro
AppointmentsCambridge-based drug discovery company Crescendo Biologics Ltd has named Theodora Harold its Chief Financial Officer. She has held this position in several early stage and growing biotechs.